Chinese biotech firm offers unproven iPS cell treatment

08/5/2008 | InformationWeek

China-based Beike Biotechnology is using a promising but untested therapy involving induced pluripotent stem cells to treat hundreds of patients -- many from Western countries -- suffering from diseases deemed incurable, such as cerebral palsy and muscular dystrophy. The company's technology, which uses a combination of umbilical-cord cells and stem cells extracted from patients, "may someday create the conditions for effective clinical treatments and industrial scale production of iPS cells," a U.S. researcher said.

View Full Article in:

InformationWeek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD